NCT06550102Recruiting
Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
Summary
This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.
Inclusion criteria
• Pediatric and adult patients below the age of 40 years • Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma • Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research • Patient and/or guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research.
Exclusion criteria
• Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland
- Sponsor
- University Children's Hospital, Zurich(Other)
- Protocol no.
- 2021-02189
- Conditions
- Hematological Malignancies
- Interventions
- —
Locations · 1
- Zurich, SwitzerlandUniversity Children's Hospital ZurichRecruiting at this site
In total, worldwide, the only site listed in the registry is recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: August 15, 2024).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.